The UTEL OTDR can be connected to the input of a UTEL OS-36 to provide test access for multiple fibres. The Optical Test Access Switches can be organised in a cascaded arrangement, which means a single UTEl OTDR can test an entire Optical Distribution Frame(ODF). The OTDR can be controlled remotely using TL1, XML or UTELs bespoke test management software.
Aetna considers pembrolizumab (Keytruda) medically necessary for the following indications: 1  Colorectal cancer - single agent therapy for. Primary treatment for unresectable metachronous metastases and previous adjuvant FOLFOX or CapeOX within the past 12 months; or.
This effect lasted at least 1.4 to 8.5 months and continued beyond this period in most patients. A similar percentage of patients had their tumor shrink at the 10 mg/kg dose. The most common side effects of Keytruda were fatigue, cough, nausea, pruritus, rash, decreased appetite, constipation, arthralgia and diarrhea. Keytruda also has the potential for severe immune-mediated side effects involving healthy organs, including the lung, colon, hormone-producing glands and liver, occurred uncommonly.